Individualized tacrolimus therapy: Insights from CYP3A5 polymorphisms and intestinal metabolism

Clin Case Rep. 2024 Sep 5;12(9):e9416. doi: 10.1002/ccr3.9416. eCollection 2024 Sep.

Abstract

CYP3A4 and CYP3A5 are the most abundant and important enzymes of the CYP3A subfamily, distributed in the liver, intestinal mucosa and kidney, and involved in tacrolimus metabolism. Here, we report a case of tacrolimus dosage refractoriness due to a genetic polymorphism of CYP3A5.

Keywords: CYP3A5; intestinal absorption; kidney transplantation; tacrolimus; therapeutic drug monitoring.

Publication types

  • Case Reports